Dr. Bart L. Scott
Medical Oncology (Medical Oncology Physician)
University Of Washington Medical Ctr, 1959 Ne Pacific St
Seattle, WA 98195
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 89
Licensed in Washington since 1999, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD00037261 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 291
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 84 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 61 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 55 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 29 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Inrebic (fedratinib dihydrochloride) | 15 |
| Hydroxyurea Other prescribers in Seattle, WA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 178 payments worth $209,824 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $61,631 |
|---|---|
| Incyte Corporation | $51,559 |
| Geron Corporation | $36,010 |
| E.r. Squibb & Sons, L.l.c. | $20,955 |
| Taiho Oncology, Inc. | $17,919 |
| Syndax Pharmaceuticals, Inc. | $10,574 |
| Sobi, Inc | $4,565 |
| Novartis Pharmaceuticals Corporation | $3,188 |
| Compensation for services other than consulting (speaking, faculty) | $133,881 |
|---|---|
| Consulting Fee | $48,958 |
| Travel and Lodging | $23,214 |
| Food and Beverage | $3,770 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Mar 1, 2025 | Compensation for services other than consulting (speaking, faculty) INQOVI · Oncology | $15,990 |
| Alexion Pharmaceuticals, Inc. May 29, 2025 | Consulting Fee | $10,920 |
| Alexion Pharmaceuticals, Inc. Mar 20, 2025 | Consulting Fee | $10,920 |
| E.r. Squibb & Sons, L.l.c. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $9,315 |
| Geron Corporation Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $8,700 |
| Geron Corporation Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $8,700 |
| Incyte Corporation Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $6,850 |
| Incyte Corporation Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $6,850 |
| Alexion Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $6,240 |
| Alexion Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,240 |
All 130 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Geron Corporation Dec 18, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,925 |
| Syndax Pharmaceuticals, Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $1,200 |
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Las Vegas, NV | $102 |
| Celgene Corporation Dec 5, 2025 | Travel and Lodging travel to Orlando, FL | $197 |
| E.r. Squibb & Sons, L.l.c. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $9,315 |
| Geron Corporation Dec 1, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ORLANDO, FL | $77.97 |
| Geron Corporation Dec 1, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ORLANDO, FL | $69.13 |
| Syndax Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,000 |
| Geron Corporation Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $1,950 |
| E.r. Squibb & Sons, L.l.c. Nov 14, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Las Vegas, NV | $515 |
| E.r. Squibb & Sons, L.l.c. Nov 14, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Las Vegas, NV | $317 |
| E.r. Squibb & Sons, L.l.c. Nov 14, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Las Vegas, NV | $276 |
| Alexion Pharmaceuticals, Inc. Nov 13, 2025 | Consulting Fee | $3,900 |
| E.r. Squibb & Sons, L.l.c. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,623 |
| Incyte Corporation Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi; Niktimvo · Hematology/Oncology | $5,480 |
| Geron Corporation Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $8,700 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $630 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $390 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $308 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $308 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $239 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Spokane, WA | $148 |
| Incyte Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $5,480 |
| Geron Corporation Oct 25, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ORLANDO, FL · in-kind | $657 |
| Geron Corporation Oct 25, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ORLANDO, FL · in-kind | $644 |
| Geron Corporation Oct 25, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ORLANDO, FL · in-kind | $484 |
| Geron Corporation Oct 22, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ANCHORAGE, AK | $87.98 |
| Geron Corporation Oct 22, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ANCHORAGE, AK | $69.36 |
| Incyte Corporation Oct 17, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Visalia, CA | $62.91 |
| Incyte Corporation Oct 16, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Visalia, CA | $693 |
| Incyte Corporation Oct 16, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Visalia, CA | $295 |
| Incyte Corporation Oct 16, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Visalia, CA | $197 |
| Incyte Corporation Oct 16, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Visalia, CA | $83.94 |
| Geron Corporation Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $8,700 |
| Incyte Corporation Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $6,850 |
| Incyte Corporation Oct 7, 2025 | Travel and Lodging Jakafi; Niktimvo · Hematology/Oncology · travel to Eugene, OR | $337 |
| Alexion Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,240 |
| Incyte Corporation Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi; Niktimvo · Hematology/Oncology | $685 |
| Incyte Corporation Sep 30, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Anchorage, AK | $488 |
| Incyte Corporation Sep 30, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Anchorage, AK | $334 |
| Incyte Corporation Sep 30, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Anchorage, AK | $183 |
| Alexion Pharmaceuticals, Inc. Sep 25, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind Company’s descriptionSpeaker Expenses | $492 |
| Alexion Pharmaceuticals, Inc. Sep 25, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind Company’s descriptionSpeaker Expenses | $460 |
| Alexion Pharmaceuticals, Inc. Sep 25, 2025 | Travel and Lodging travel to Seattle, WA | $81.98 |
| Alexion Pharmaceuticals, Inc. Sep 25, 2025 | Travel and Lodging travel to Seattle, WA | $67.94 |
| Alexion Pharmaceuticals, Inc. Sep 24, 2025 | Travel and Lodging travel to Anchorage, AK | $20.27 |
| Alexion Pharmaceuticals, Inc. Sep 24, 2025 | Travel and Lodging travel to Anchorage, AK | $15.95 |
| Incyte Corporation Sep 23, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Spokane, WA | $317 |
| Apellis Pharmaceuticals, Inc. Sep 22, 2025 | Consulting Fee Empaveli · Hematology | $2,739 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 20, 2025 | Consulting Fee | $146 |
| Geron Corporation Sep 18, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ANCHORAGE, AK · in-kind | $1,497 |
| Geron Corporation Sep 18, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ANCHORAGE, AK · in-kind | $438 |
| Geron Corporation Sep 18, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to ANCHORAGE, AK · in-kind | $407 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $4,290 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Austin, TX · in-kind Company’s descriptionConsulting Expenses | $360 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Austin, TX · in-kind Company’s descriptionConsulting Expenses | $163 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Seattle, WA Company’s descriptionConsulting Expenses | $65.01 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Austin, TX Company’s descriptionConsulting Expenses | $49.93 |
| Alexion Pharmaceuticals, Inc. Sep 16, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Austin, TX Company’s descriptionConsulting Expenses | $38.31 |
| Alexion Pharmaceuticals, Inc. Sep 15, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Austin, TX · in-kind Company’s descriptionConsulting Expenses | $218 |
| Alexion Pharmaceuticals, Inc. Sep 15, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Seattle, WA Company’s descriptionConsulting Expenses | $90.97 |
| Syndax Pharmaceuticals, Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $5,600 |
| Alexion Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $6,240 |
| Alexion Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,240 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee Fabhalta · Immunology | $3,188 |
| Sobi, Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $2,830 |
| E.r. Squibb & Sons, L.l.c. Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,623 |
| Incyte Corporation Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $6,850 |
| Syndax Pharmaceuticals, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY Company’s descriptionBranded Speaker Training | $1,200 |
| Alexion Pharmaceuticals, Inc. Jul 24, 2025 | Consulting Fee | $2,730 |
| E.r. Squibb & Sons, L.l.c. Jul 23, 2025 | Consulting Fee | $2,565 |
| Incyte Corporation Jul 22, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Tucson, AZ | $572 |
| Incyte Corporation Jul 22, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Tucson, AZ | $464 |
| Incyte Corporation Jul 22, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Tucson, AZ | $448 |
| Incyte Corporation Jul 22, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Tucson, AZ | $158 |
| Incyte Corporation Jul 22, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Tucson, AZ | $123 |
| Syndax Pharmaceuticals, Inc. Jul 16, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to VANCOUVER, WA · in-kind | $432 |
| Incyte Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $5,480 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $2,681 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Jose, CA · in-kind Company’s descriptionSpeaker Expenses | $1,007 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Seattle, WA | $84.95 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Seattle, WA | $76.03 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging travel to Seattle, WA | $71.20 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Palo Alto, CA | $57.59 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to San Jose, CA | $52.95 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionSpeaker Expenses | $278 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to Seattle, WA · in-kind Company’s descriptionSpeaker Expenses | $163 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionSpeaker Expenses | $146 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to Oakland, CA | $75.77 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to Oakland, CA | $66.70 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging travel to San Francisco, CA | $37.96 |
| Incyte Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Incyte Corporation Jun 24, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Spokane, WA | $486 |
| Incyte Corporation Jun 24, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Spokane, WA | $261 |
| Incyte Corporation Jun 24, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Spokane, WA | $150 |
| Alexion Pharmaceuticals, Inc. Jun 12, 2025 | Consulting Fee | $2,730 |
| Incyte Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Alexion Pharmaceuticals, Inc. May 29, 2025 | Consulting Fee | $10,920 |
| Incyte Corporation May 27, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $685 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $518 |
| Incyte Corporation May 13, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $5,480 |
| Incyte Corporation May 6, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Sacramento, CA | $562 |
| Incyte Corporation May 6, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Sacramento, CA | $250 |
| Incyte Corporation May 6, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Sacramento, CA | $248 |
| Geron Corporation Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $1,950 |
| Alexion Pharmaceuticals, Inc. Apr 25, 2025 | Travel and Lodging travel to Tampa, FL · in-kind Company’s descriptionConsulting Expenses | $416 |
| Alexion Pharmaceuticals, Inc. Apr 24, 2025 | Travel and Lodging travel to Tampa, FL · in-kind Company’s descriptionConsulting Expenses | $377 |
| Alexion Pharmaceuticals, Inc. Apr 24, 2025 | Travel and Lodging travel to Tampa, FL · in-kind Company’s descriptionConsulting Expenses | $309 |
| Incyte Corporation Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) Niktimvo · Oncology | $457 |
| Sobi, Inc Apr 13, 2025 | Travel and Lodging Vonjo · Hematology/Oncology · travel to San Francisco, CA | $10.94 |
| Sobi, Inc Apr 12, 2025 | Travel and Lodging Vonjo · Hematology/Oncology · travel to San Francisco, CA | $9.09 |
| Geron Corporation Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $1,950 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $343 |
| Alexion Pharmaceuticals, Inc. Mar 20, 2025 | Consulting Fee | $10,920 |
| Taiho Oncology, Inc. Mar 1, 2025 | Compensation for services other than consulting (speaking, faculty) INQOVI · Oncology | $15,990 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $537 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $448 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $243 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $190 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $190 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $70.00 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL · in-kind | $70.00 |
| Taiho Oncology, Inc. Mar 1, 2025 | Travel and Lodging INQOVI · Oncology · travel to Miami Beach, FL | $62.92 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $185 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Fort Worth, TX · in-kind Company’s descriptionConsulting Expenses | $366 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $357 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to SeaTac, WA Company’s descriptionConsulting Expenses | $65.78 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionConsulting Expenses | $59.91 |
| Sobi, Inc Feb 13, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $1,388 |
| Geron Corporation Feb 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $1,950 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $1,070,280 in research payments for these studies, mostly to the institutions running them.
- A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
Taiho Oncology, Inc. - An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc. - Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation · Active, not recruiting · NCT02598661 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - PAC601
Sobi, Inc - An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis
Geron Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.